Inositols: From Established Knowledge to Novel Approaches
Open accessThe DOI matches its Crossref record; 200 of the 201 references it cites were found in a registry or an index.
Abstract
Myo-inositol (myo-Ins) and D-chiro-inositol (D-chiro-Ins) are natural compounds involved in many biological pathways. Since the discovery of their involvement in endocrine signal transduction, myo-Ins and D-chiro-Ins supplementation has contributed to clinical approaches in ameliorating many gynecological and endocrinological diseases. Currently both myo-Ins and D-chiro-Ins are well-tolerated, effective alternative candidates to the classical insulin sensitizers, and are useful treatments in preventing and treating metabolic and reproductive disorders such as polycystic ovary syndrome (PCOS), gestational diabetes mellitus (GDM), and male fertility disturbances, like sperm abnormalities. Moreover, besides metabolic activity, myo-Ins and D-chiro-Ins deeply influence steroidogenesis, regulating the pools of androgens and estrogens, likely in opposite ways. Given the complexity of inositol-related mechanisms of action, many of their beneficial effects are still under scrutiny. Therefore, continuing research aims to discover new emerging roles and mechanisms that can allow clinicians to tailor inositol therapy and to use it in other medical areas, hitherto unexplored. The present paper outlines the established evidence on inositols and updates on recent research, namely concerning D-chiro-Ins involvement into steroidogenesis. In particular, D-chiro-Ins mediates insulin-induced testosterone biosynthesis from ovarian thecal cells and directly affects synthesis of estrogens by modulating the expression of the aromatase enzyme. Ovaries, as well as other organs and tissues, are characterized by a specific ratio of myo-Ins to D-chiro-Ins, which ensures their healthy state and proper functionality. Altered inositol ratios may account for pathological conditions, causing an imbalance in sex hormones. Such situations usually occur in association with medical conditions, such as PCOS, or as a consequence of some pharmacological treatments. Based on the physiological role of inositols and the pathological implications of altered myo-Ins to D-chiro-Ins ratios, inositol therapy may be designed with two different aims: (1) restoring the inositol physiological ratio; (2) altering the ratio in a controlled way to achieve specific effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, insulin resistance (IR) has a central role in its pathogenesis [5–7].”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“During the secondary signaling mechanisms, inositol triphosphate (IP3) will also be released, which can be converted to free myoinositol by inositol-monophosphatase [6].”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, DCI is an aromatase inhibitor and promotes glycogen synthase, which inhibits the conversion of androgens to estrogens, resulting in the accumulation of androgens and lack of estrogens.”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, in the short term, it can improve insulin levels, thus promoting SHBG production [6].”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Inositols are considered insulin sensitizers, as they modulate the members of insulin signaling pathways [6].”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [6]
Experimental — accuracy not yet measured
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
- Retracted
Marín, I. H., Picconi, O., Laganà, A. S., Costabile, L., & Unfer, V. (2021) · PubMed · doi:10.26355/eurrev_202104_25743 · Cited by 31
Self-citationRetracted(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study
(1991) · The Lancet · doi:10.1016/0140-6736(91)90133-a · Cited by 3,472
Phosphoinositides in cell regulation and membrane dynamics
Di Paolo, G., & De Camilli, P. (2006) · Nature · doi:10.1038/nature05185 · Cited by 2,790
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954 · cited 1×
“Within the male population a potential target for D-chiro-Ins administration might be elderly men suffering from late-onset hypogonadism (LOH), who present with an impaired production of adequate levels of testosterone by testis and sperm cells, resulting in androgen deficiency [142,143].”
BackgroundSneddon, J., Densem, J. W., Wald, N. J., Frost, C., Stone, R., & Gnant, M. (1991) · PubMed · Cited by 1,812
The causes of reduced fertility with cryopreserved semen
Watson, P. F. (2000) · Animal Reproduction Science · doi:10.1016/s0378-4320(00)00099-3 · Cited by 1,553
Sambuy, Y., De Angelis, I., Ranaldi, G., Scarino, M. L., Stammati, A., & Zucco, F. (2005) · Cell Biology and Toxicology · doi:10.1007/s10565-005-0085-6 · Cited by 1,488 · cited 1×
“discovered that, in presence of α-LA, myo-Ins increased its passage across the Caco-2 cell monolayer, used as a standard in vitro model of intestinal epithelium [182].”
BackgroundPrevention of Neural-Tube Defects with Folic Acid in China
Berry, R. J., Li, Z., Erickson, J. D., Li, S., Moore, C. A., Wang, H., Mulinare, J., Zhao, P., Wong, L.-Y. C., Gindler, J., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911113412001 · Cited by 1,299
Prevention of Neural-Tube Defects with Folic Acid in China
(1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412424 · Cited by 1,073
Greene, N. D. E., & Copp, A. J. (2014) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-062012-170354 · Cited by 629 · cited 1×
“Overall, susceptibility to NTDs is thought to be influenced by the interplay between genetic risk factors and environmental factors, including maternal nutrition [102].”
BackgroundSelf-citationNestler, J. E., Jakubowicz, D. J., Falcon de Vargas, A., Brik, C., Quintero, N., & Medina, F. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.6.4886 · Cited by 617
Self-citationFolic Acid Food Fortification—Its History, Effect, Concerns, and Future Directions
Crider, K. S., Bailey, L. B., & Berry, R. J. (2011) · Nutrients · doi:10.3390/nu3030370 · Cited by 608
Miyakawa, H., Woo, S. K., Dahl, S. C., Handler, J. S., & Kwon, H. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2538 · Cited by 580 · cited 1×
“This prevents an increase in the concentration of inorganic ions without perturbing the activity of macromolecules [9].”
BackgroundMacDonald, A. A., Herbison, G. P., Showell, M., & Farquhar, C. M. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmp047 · Cited by 539 · cited 1×
“Obese men are often characterized by low circulating androgens but elevated levels of circulating estrone and 17β-estradiol [149,150].”
BackgroundLithium side effects and toxicity: prevalence and management strategies
Gitlin, M. (2016) · International Journal of Bipolar Disorders · doi:10.1186/s40345-016-0068-y · Cited by 531
Stewart, E. A., Laughlin-Tommaso, S. K., Catherino, W. H., Lalitkumar, S., Gupta, D., & Vollenhoven, B. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.43 · Cited by 531 · cited 1×
“Although leiomyomas are mostly asymptomatic and tend to resolve spontaneously after menopause [154], some women may experiment severe symptoms, such as pelvic pain, dysmenorrhea and bleeding.”
BackgroundGestational diabetes mellitus: an updated overview
Chiefari, E., Arcidiacono, B., Foti, D., & Brunetti, A. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0607-5 · Cited by 522 · cited 1×
“This condition may predispose the mother to several risks such as gestational hypertension, cesarean section, and later development of type 2 diabetes, and the baby to preterm birth, congenital abnormalities, macrosomia, being large for gestational age (LGA), neonatal hypoglycemia and respiratory distress syndrome [57…”
BackgroundOvulatory and Metabolic Effects of d-Chiro-Inositol in the Polycystic Ovary Syndrome
Nestler, J. E., Jakubowicz, D. J., Reamer, P., Gunn, R. D., & Allan, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401703 · Cited by 518 · cited 1×
“This “ovarian paradox hypothesis” may help to explain why supplementation with Dchiro-Ins alone, especially at high doses (>1200 mg) and for a prolonged time (>3 months), cannot be considered an effective approach to manage PCOS, despite some encouraging results in 1999 [41].”
Self-citationIncreased Estrogen Production in Obese Men*
SCHNEIDER, G., KIRSCHNER, M. A., BERKOWITZ, R., & ERTEL, N. H. (1979) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-48-4-633 · Cited by 506 · cited 1×
“Obese men are often characterized by low circulating androgens but elevated levels of circulating estrone and 17β-estradiol [149,150].”
BackgroundNair, A., Morsy, M. A., & Jacob, S. (2018) · Drug Development Research · doi:10.1002/ddr.21461 · Cited by 474 · cited 1×
“These doses provided approximate daily amounts of 5, 10 and 20 mg D-chiro-Ins/mouse, matching human doses of 1200, 2400 and 4800 mg/day respectively [169].”
BackgroundMetformin versus placebo in obese pregnant women without diabetes mellitus
Syngelaki, A., Nicolaides, K. H., Balani, J., Hyer, S., Akolekar, R., Kotecha, R., Pastides, A., & Shehata, H. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509819 · Cited by 394
Maternal obesity and risk of neural tube defects: a metaanalysis
Rasmussen, S. A., Chu, S. Y., Kim, S. Y., Schmid, C. H., & Lau, J. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.04.021 · Cited by 390 · cited 1×
“In addition to the direct requirement for myo-Ins in formation of the neural tube, suboptimal inositol status may also play a role in the known association of maternal diabetes and obesity with NTDs [91,92].”
BackgroundTulandi, T., Martin, J., Al-Fadhli, R., Kabli, N., Forman, R., Hitkari, J., Librach, C., Greenblatt, E., & Casper, R. F. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.03.014 · Cited by 370 · cited 1×
“Indeed, especially for Letrozole, it seems to be contraindicated for the treatment of premenopausal women, since there is an increased risk of fetal cardiac and skeletal malformations associated with its administration [167].”
BackgroundCloning of the cDNa for a Na+/myo-inositol cotransporter, a hypertonicity stress protein.
Kwon, H. M., Yamauchi, A., Uchida, S., Preston, A. S., Garcia-Perez, A., Burg, M. B., & Handler, J. S. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42695-6 · Cited by 342
Vanky, E., Stridsklev, S., Heimstad, R., Romundstad, P., Skogøy, K., Kleggetveit, O., Hjelle, S., von Brandis, P., Eikeland, T., Flo, K., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0853 · Cited by 315 · cited 1×
“Indeed, for the purposes of GDM prevention, earlier observational studies [65–67] suggested that metformin administration could be associated with lower risk of GDM development, but these results were not confirmed by subsequent trials [68].”
ResultIdentification of proteomic differences in asthenozoospermic sperm samples
Martinez-Heredia, J., de Mateo, S., Vidal-Taboada, J. M., Ballesca, J. L., & Oliva, R. (2008) · Human Reproduction · doi:10.1093/humrep/den024 · Cited by 279 · cited 1×
“Furthermore, these cells exhibited reduced motility [113], suggesting that inositol pathways are crucial to support sperm cell movement.”
BackgroundD‐Chiro‐Inositol – Its Functional Role in Insulin Action and its Deficit in Insulin Resistance
Larner, J. (2002) · Journal of Diabetes Research · doi:10.1080/15604280212528 · Cited by 277 · cited 1×
“Data were retrieved and adapted from the references [18,30,32].”
MethodChiswick, C., Reynolds, R. M., Denison, F., Drake, A. J., Forbes, S., Newby, D. E., Walker, B. R., Quenby, S., Wray, S., Weeks, A., et al. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00219-3 · Cited by 260 · cited 1×
“However, evidence fails to support other beneficial effects for this molecule on top of promoting euglycemia [63,64].”
BackgroundERICKSO, G. F., HSUEH, A. J. W., QUIGLEY, M. E., REBAR, R. W., & YEN, S. S. C. (1979) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-49-4-514 · Cited by 251
Tissue physiology and pathology of aromatase
Stocco, C. (2012) · Steroids · doi:10.1016/j.steroids.2011.10.013 · Cited by 246 · cited 1×
“In support to this idea, myo-Ins is involved in modulating FSH signaling, and FSH stimulates aromatase synthesis, a fundamental step for conversion of androgens to estrogens and for follicle maturation [126].”
BackgroundInositol prevents folate-resistant neural tube defects in the mouse
Greene, N. D. E., & Copp, A. J. (1997) · Nature Medicine · doi:10.1038/nm0197-60 · Cited by 224 · cited 1×
“Inositol supplementation reduces the incidence of spina bifida in these mice (Figure 6), whether by maternal supplementation or in cultured embryos [86].”
BackgroundSelf-citationLow Urinary chiro-Inositol Excretion in Non-Insulin-Dependent Diabetes Mellitus
Kennington, A. S., Hill, C. R., Craig, J., Bogardus, C., Raz, I., Ortmeyer, H. K., Hansen, B. C., Romero, G., & Larner, J. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008093230603 · Cited by 218 · cited 1×
“Notably, pathological conditions, like type 2 diabetes, show decreased insulin sensitivity in many tissues, leading to reduced epimerase activity and lower D-chiro-Ins production [18,38].”
BackgroundMyo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials
Unfer, V., Facchinetti, F., Orrù, B., Giordani, B., & Nestler, J. (2017) · Endocrine Connections · doi:10.1530/ec-17-0243 · Cited by 188 · cited 1×
“In contrast, several lines of evidence proved myo-Ins efficacy and safety in managing PCOS symptoms and improving outcomes [43], with the most promising clinical results observed in obese, insulin-resistant PCOS women, when combining myo-Ins and D-chiro-”
ResultSelf-citationNestler, J. (1997) · Seminars in Reproductive Medicine · doi:10.1055/s-2007-1016294 · Cited by 184 · cited 1×
“Insulin resistance and compensatory hyperinsulinemia seem to have a central role in PCOS pathogenesis [34,35], contributing both directly and indirectly to hyperandrogenism development and related clinical features.”
BackgroundSelf-citationGlueck, C. J. (2004) · Human Reproduction · doi:10.1093/humrep/deh109 · Cited by 183
Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease
Bizzarri, M., Fuso, A., Dinicola, S., Cucina, A., & Bevilacqua, A. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1206887 · Cited by 183 · cited 1×
“When the endogenous production of myo-Ins is insufficient to meet the human biological needs, an adequate intake of inositol either through specific food and/or supplements becomes necessary [14] (Figure 2).”
BackgroundSelf-citationChiu, T. T. Y., Rogers, M. S., Law, E. L. K., Briton-Jones, C. M., Cheung, L. P., & Haines, C. J. (2002) · Human Reproduction · doi:10.1093/humrep/17.6.1591 · Cited by 182 · cited 1×
“Ten years later the same group discovered that a correlation exists between myo-Ins concentration in follicular fluid (FF) and oocyte quality [133].”
BackgroundSelf-citationObesity and testicular function
Mah, P. M., & Wittert, G. A. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.06.007 · Cited by 180 · cited 1×
“It has been proposed that increased peripheral aromatization of testosterone in obese men may enhance central estradiol signaling, suppressing gonadotropin production and contributing to a sustained state of hypogonadotropic hypogonadism [152].”
BackgroundEffects of Hyperinsulinemia and Obesity on Risk of Neural Tube Defects among Mexican Americans
Hendricks, K. A., Nuno, O. M., Suarez, L., & Larsen, R. (2001) · Epidemiology · doi:10.1097/00001648-200111000-00009 · Cited by 170 · cited 1×
“As such, hyperinsulinemia has been proposed as a putative mechanism which determines NTD risk in obese women with diabetes [93].”
BackgroundInositols in Insulin Signaling and Glucose Metabolism
Bevilacqua, A., & Bizzarri, M. (2018) · International Journal of Endocrinology · doi:10.1155/2018/1968450 · Cited by 165 · cited 1×
“This could explain why tissues with high glucose utilization, like brain, heart and ovary contain a large amount of myo-Ins compared with other tissues [17].”
BackgroundSelf-citationMosley, B. S., Cleves, M. A., Siega-Riz, A. M., Shaw, G. M., Canfield, M. A., Waller, D. K., Werler, M. M., Hobbs, C. A., & Study, F. T. N. B. D. P. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn331 · Cited by 158 · cited 1×
“However, FA alone does not provide complete prevention of recurrence or occurrence of NTDs, leading to the description of ‘folic acid resistant NTDs’ [106].”
BackgroundSumitani, H., Shozu, M., Segawa, T., Murakami, K., Yang, H.-J., Shimada, K., & Inoue, M. (2000) · Endocrinology · doi:10.1210/en.141.10.3852 · Cited by 156 · cited 1×
“In accordance, several groups reported that aromatase is significantly overexpressed in myoma cells compared with the adjacent normal myometrium [157,158], leading to a high level of in situ estrogens that may contribute to the growth advantage of myomas through an intracrine/autocrine mechanism [159].”
BackgroundJauniaux, E., Hempstock, J., Teng, C., Battaglia, F. C., & Burton, G. J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1513 · Cited by 153 · cited 3×
“Myo-Ins, as well as other polyols, may have multiple other functions during embryogenesis, acting as osmolytes to promote expansion of the amniotic and coelomic cavities, providing precursors of cell membrane components and supplying substrates for the pentose phosphate pathway necessary for the synthesis of nucleic a…”
BackgroundAlpha-lactalbumin: A new carrier for vitamin D3 food enrichment
Delavari, B., Saboury, A. A., Atri, M. S., Ghasemi, A., Bigdeli, B., Khammari, A., Maghami, P., Moosavi‐Movahedi, A. A., Haertlé, T., & Goliaei, B. (2014) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2014.10.017 · Cited by 152 · cited 1×
“Recently, researchers proposed the concomitant administration of myo-Ins and the milk protein α-LA, already known for its properties as a nutrient as well as for enhancing the absorption of metal ions and vitamins [178,179].”
BackgroundHigh Aromatase Expression in Uterine Leiomyoma Tissues of African-American Women
Ishikawa, H., Reierstad, S., Demura, M., Rademaker, A. W., Kasai, T., Inoue, M., Usui, H., Shozu, M., & Bulun, S. E. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2327 · Cited by 151 · cited 1×
“In accordance, several groups reported that aromatase is significantly overexpressed in myoma cells compared with the adjacent normal myometrium [157,158], leading to a high level of in situ estrogens that may contribute to the growth advantage of myomas through an intracrine/autocrine mechanism [159].”
BackgroundEstrogen in the male: a historical perspective†
Hess, R. A., & Cooke, P. S. (2018) · Biology of Reproduction · doi:10.1093/biolre/ioy043 · Cited by 151 · cited 1×
“Moreover, excessive estradiol stimulation has been postulated to play an exacerbating role in the progression of obesity and metabolic dysregulation [148].”
BackgroundShaw, N. D., Histed, S. N., Srouji, S. S., Yang, J., Lee, H., & Hall, J. E. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2108 · Cited by 149 · cited 1×
“These agents decrease estrogen biosynthesis and reduce the negative hypothalamic feedback on GnRH and FSH [166], but not without side effects.”
BackgroundInsulin Sensitizers for Polycystic Ovary Syndrome
Baillargeon, J., Iuorno, M. J., & Nestler, J. E. (2003) · Clinical Obstetrics & Gynecology · doi:10.1097/00003081-200306000-00011 · Cited by 148 · cited 1×
“Insulin resistance and compensatory hyperinsulinemia seem to have a central role in PCOS pathogenesis [34,35], contributing both directly and indirectly to hyperandrogenism development and related clinical features.”
BackgroundSelf-citationFacchinetti, F., Bizzarri, M., Benvenga, S., D’Anna, R., Lanzone, A., Soulage, C., Di Renzo, G. C., Hod, M., Cavalli, P., Chiu, T. T., et al. (2015) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2015.09.024 · Cited by 145 · cited 1×
“In 2013, an International Consensus Conference on myo-Ins and D-chiro-Ins in Obstetrics and Gynecology recognized that both inositols are involved in PCOS pathogenesis and a compelling body of clinical evidence demonstrated that their supplementation could be beneficial in improving metabolic and reproductive features…”
BackgroundSelf-citationSun, T.-H., Heimark, D. B., Nguygen, T., Nadler, J. L., & Larner, J. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00313-3 · Cited by 144 · cited 3×
“Notably, pathological conditions, like type 2 diabetes, show decreased insulin sensitivity in many tissues, leading to reduced epimerase activity and lower D-chiro-Ins production [18,38].”
BackgroundMethodThe D-chiro-inositol paradox in the ovary
Carlomagno, G., Unfer, V., & Roseff, S. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.05.027 · Cited by 139 · cited 1×
“Indeed, according to the so-called “ovarian paradox”, ovaries never become insulin resistant, and therefore, the compensatory hyperinsulinemia overstimulates ovarian epimerase activity, causing excessive D-chiro-Ins synthesis at the expense of myo-Ins concentration [39,40] (Figure 5).”
BackgroundSelf-citationBerry, G. T., Mallee, J. J., Kwon, H. M., Rim, J. S., Mulla, W. R., Muenke, M., & Spinner, N. B. (1995) · Genomics · doi:10.1016/0888-7543(95)80052-n · Cited by 135
D-chiro-inositol metabolism in diabetes mellitus.
Ostlund, R. E., McGill, J. B., Herskowitz, I., Kipnis, D. M., Santiago, J. V., & Sherman, W. R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.21.9988 · Cited by 131 · cited 1×
“0 μM, which is significantly higher [185,186].”
Shaw, G. M., Quach, T., Nelson, V. E., Carmichael, S. L., Schaffer, D., Selvin, S., & Yang, W. (2003) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/78.5.972 · Cited by 129
Cheang, K. I., Baillargeon, J.-P., Essah, P. A., Ostlund, R. E., Apridonize, T., Islam, L., & Nestler, J. E. (2008) · Metabolism · doi:10.1016/j.metabol.2008.05.008 · Cited by 129 · cited 1×
“The same group tried to reproduce their findings supplementing PCOS women with 2400 mg of D-chiro-Ins for 6 weeks [42].”
BackgroundSelf-citationMyoinositol: Does It Improve Sperm Mitochondrial Function and Sperm Motility?
Condorelli, R. A., Vignera, S. L., Bellanca, S., Vicari, E. S. D., & Calogero, A. E. (2012) · Urology · doi:10.1016/j.urology.2012.03.005 · Cited by 127
Heimark, D., McAllister, J., & Larner, J. (2014) · Endocrine Journal · doi:10.1507/endocrj.ej13-0423 · Cited by 126 · cited 5×
“In spermatozoa, myo-Ins behaves as second messenger modulating the intracellular Ca2+ levels that regulate mitochondrial oxidative metabolism and ATP production [111].”
BackgroundInfluentialGroenen, P. M. W., Peer, P. G. M., Wevers, R. A., Swinkels, D. W., Franke, B., Mariman, E. C. M., & Steegers‐Theunissen, R. P. M. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(03)00807-x · Cited by 124 · cited 1×
“In humans, an association of low maternal serum myo-Ins levels with occurrence of spina bifida was identified [79], suggesting a possible link between insufficient inositol and NTDs as reported in rodent models.”
BackgroundOn the Association Between Valproate and Polycystic Ovary Syndrome
Genton, P., Bauer, J. M., Duncan, S., Taylor, A. E., Balen, A. H., Eberle, A., Pedersen, B., Salas‐Puig, X., & Sauer, M. V. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.28899.x · Cited by 119
Oxidative Stress and Male Fertility: Role of Antioxidants and Inositols
Luca, M. N. D., Colone, M., Gambioli, R., Stringaro, A., & Unfer, V. (2021) · Antioxidants · doi:10.3390/antiox10081283 · Cited by 117
Self-citationInositol safety: clinical evidences.
Carlomagno, G., & Unfer, V. (2011) · PubMed · Cited by 114
Self-citationAl-Hendy, A. A., Roshdy, Rajaratnam, Maitra, S. R., Sabry, M., & Allah, A. (2013) · International Journal of Women s Health · doi:10.2147/ijwh.s41021 · Cited by 113
Baker, L. W., Piddington, R., Goldman, A., Egler, J. M., & Moehring, J. (1990) · Diabetologia · doi:10.1007/bf00400202 · Cited by 112 · cited 1×
“In these models, supplementation with myo-Ins restored myo-Ins tissue content and reduced the incidence of NTDs, suggesting the involvement of lowered myo-Ins in the mechanism of diabetic embryopathy [100,101].”
MethodA meta-analysis of polycystic ovary syndrome in women taking valproate for epilepsy
Hu, X., Wang, J., Dong, W., Fang, Q., Hu, L., & Liu, C. (2011) · Epilepsy Research · doi:10.1016/j.eplepsyres.2011.07.006 · Cited by 111
(2012) · PubMed · Cited by 111
Self-citationDinicola, S., Minini, M., Unfer, V., Verna, R., Cucina, A., & Bizzarri, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102187 · Cited by 110 · cited 1×
“In humans a large amount of myo-Ins (about 1 g/day) is provided by dietary intake, with cereals, legumes, oil seeds and nuts representing the main sources [11], but a significant proportion of daily requirements is still synthesized endogenously (about 4 g/day), with kidneys being the major contributors.”
BackgroundSelf-citationRNA-seq reveals conservation of function among the yolk sacs of human, mouse, and chicken
Cindrová‐Davies, T., Jauniaux, E. R. M., Elliot, M. G., Gong, S., Burton, G. J., & Charnock‐Jones, D. S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1702560114 · Cited by 109 · cited 1×
“It has been hypothesized that genetic defects of myo-inositol synthase ISYNA1, which is also expressed in placenta and yolk sac [80,81], may result in low maternal and/or embryonic intracellular myo-Ins, predisposing to NTD pathogenesis.”
BackgroundPolycystic ovary syndrome in women using valproate: A review
Bilo, L., & Meo, R. (2008) · Gynecological Endocrinology · doi:10.1080/09513590802288259 · Cited by 106
Reflections on inositol(s) for PCOS therapy: steps toward success
Nestler, J. E., & Unfer, V. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1054802 · Cited by 106 · cited 2×
“Intracellularly, myo-Ins promotes GLUT4 translocation to the plasma membrane to enhance glucose uptake, inhibits adenylate cyclase and reduces free fatty acid release from adipose tissue [15,16].”
BackgroundSelf-citationUnfer, V., Carlomagno, G., Papaleo, E., Vailati, S., Candiani, M., & Baillargeon, J.-P. (2014) · Reproductive Sciences · doi:10.1177/1933719113518985 · Cited by 105 · cited 3×
“In fact, the increase in D-chiro-Ins concentration promotes androgen synthesis, meanwhile myo-Ins depletion worsens FSH signaling and oocyte quality [21,40].”
BackgroundSelf-citationAromatase in the Normal Breast and Breast Cancer
Brodie, A. M. H., Lü, Q., & Nakamura, J. (1997) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(97)80024-6 · Cited by 104 · cited 1×
“Furthermore, it is noteworthy that neoplastic tissues express high levels of the aromatase enzyme compared with the lower expression observed in non-neoplastic (normal) tissues [156].”
BackgroundA review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome
Abdalla, M. A., Deshmukh, H., Atkin, S., & Sathyapalan, T. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820938305 · Cited by 103 · cited 1×
“The effectiveness of insulin-sensitizing drugs, such as metformin and thiazolidinediones, in improving ovulatory function and reducing androgen excess in PCOS patients provided additional evidence to support the pathogenic role of insulin resistance in PCOS patients [36].”
BackgroundInositols in polycystic ovary syndrome: An overview on the advances
Facchinetti, F., Unfer, V., Dewailly, D., Kamenov, Z. A., Diamanti-Kandarakis, E., Laganà, A. S., Nestler, J. E., & Soulage, C. O. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.002 · Cited by 102
Self-citationBenelli, E., Del Ghianda, S., Di Cosmo, C., & Tonacchera, M. (2016) · International Journal of Endocrinology · doi:10.1155/2016/3204083 · Cited by 100
Kamenov, Z., & Gateva, A. (2020) · Molecules · doi:10.3390/molecules25235566 · Cited by 100 · cited 1×
“However, 25% to 75% of patients treated with myo-Ins may still be resistant to treatment [171].”
BackgroundSelf-citationHuang, L. C. (1993) · Endocrinology · doi:10.1210/en.132.2.652 · Cited by 99 · cited 1×
“Indeed, when injected intravenously, these compounds dose-dependently reduced hyperglycemia in streptozotocin-induced diabetic rats, while when injected intraperitoneally, they stimulated labeled glucose incorporation into glycogen in rat diaphragm muscle [26].”
BackgroundCabrera-Cruz, H., Oróstica, L., Plaza-Parrochia, F., Torres-Pinto, I., Romero, C., & Vega, M. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00162.2019 · Cited by 98 · cited 1×
“Through all these mechanisms myo-Ins and D-chiro-Ins may exert their insulinsensitizing effect thereby decreasing insulin requirements, which are consequently reflected by lower circulating insulin concentrations [23].”
BackgroundYap, A., Nishiumi, S., Yoshida, K., & Ashida, H. (2007) · Cytotechnology · doi:10.1007/s10616-007-9107-y · Cited by 97
Testosterone replacement therapy: for whom, when and how?
Tsametis, C. P., & Isidori, A. M. (2018) · Metabolism · doi:10.1016/j.metabol.2018.03.007 · Cited by 96 · cited 2×
“Testosterone replacement therapy (TRT) is widely used for the treatment of LOH, although there is still an extensive debate whether it should be administered to men with this condition [142].”
BackgroundAl-Hendy, A. A., Diamond, M. P., El‐Sohemy, A., & Halder, S. K. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4011 · Cited by 94 · cited 1×
“Therefore, lowering estrogen levels could be clearly considered a valid therapeutic approach for fibroid management [160].”
BackgroundThe administration of l-thyroxine as soft gel capsule or liquid solution
Vita, R., Fallahi, P., Antonelli, A., & Benvenga, S. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.918101 · Cited by 93
Self-citationLaganà, A. S., Vitagliano, A., Noventa, M., Ambrosini, G., & D’Anna, R. (2018) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-018-4861-y · Cited by 93 · cited 1×
“including eight RCTs and a total of 812 patients concluded that oral myo-Ins is able to reduce the amount of FSH in both PCOS and non-PCOS women undergoing IVF, while decreasing the length of controlled ovarian hyperstimulation only in PCOS patients [137].”
BackgroundSelf-citationInositol, neural tube closure and the prevention of neural tube defects
Greene, N. D. E., Leung, K., & Copp, A. J. (2016) · Birth Defects Research · doi:10.1002/bdra.23533 · Cited by 91 · cited 2×
“Inositol status appears to be associated with susceptibility to neural tube defects (NTDs), a group of congenital malformations affecting the developing brain and spinal cord [76].”
BackgroundSelf-citationBiology of Inositols and Phosphoinositides
Majumder, A. L., & Biswas, B. (2006) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/0-387-27600-9 · Cited by 88
Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovary syndrome
Glueck, C. J., Pranikoff, J., Aregawi, D., & Wang, P. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.03.036 · Cited by 88
Godfrey, K. M., Barton, S. J., El‐Heis, S., Kenealy, T. W., Nield, H., Baker, P. N., Chong, Y. S., Cutfield, W. S., Chan, S., NiPPeR Study Group, et al. (2021) · Diabetes Care · doi:10.2337/dc20-2515 · Cited by 85 · cited 1×
“Almost simultaneously, the NiPPeR international multicenter double-blind randomized controlled trial was published [75], acting as an outside voice among the previous studies.”
BackgroundSelf-citationBevilacqua, A., Dragotto, J., Giuliani, A., & Bizzarri, M. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27623 · Cited by 84 · cited 1×
“contributed to the first demonstration in a pre-clinical model of how the myo-Ins to D-chiro-Ins ratio influences ovarian physiology [46].”
BackgroundSelf-citationCalogero, A. E., Gullo, G., La Vignera, S., Condorelli, R. A., & Vaiarelli, A. (2015) · Andrology · doi:10.1111/andr.12025 · Cited by 81 · cited 1×
“Besides improving semen characteristics, myo-Ins administration also rebalanced the levels of key reproductive hormones, such as LH, FSH and Inhibin-B [120].”
BackgroundStereochemistry of the myo-inositol-1-phosphate synthase reaction.
Loewus, M. W., Loewus, F. A., Brillinger, G. U., Otsuka, H., & Floss, H. G. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)70191-4 · Cited by 80 · cited 1×
“Then, through inositol monophosphatase-1 (IMPA-1 or IMPase), InsP3 is dephosphorylated into free myo-Ins [13].”
BackgroundWong, Y. H., Kalmbach, S. J., Hartman, B. K., & Sherman, W. R. (1987) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1987.tb05682.x · Cited by 80 · cited 1×
“Endogenously, myo-Ins is synthetized from glucose-6-phosphate (G6P), which is isomerized to inositol-3-phosphate (InsP3) by D-3-myo-inositol-phosphate synthase enzyme (inositol synthase, Ino1, or MIPS1) [12].”
BackgroundKamenov, Z., Kolarov, G., Gateva, A., Carlomagno, G., & Genazzani, A. D. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2014.964640 · Cited by 80 · cited 1×
“, patients responding to myo-Ins supplementation showed significantly lower testosterone levels, higher SHBG and lower free androgen index [172], while in another study by Kamenov and colleagues most of the patients resistant to myo-Ins therapy were obese women [173].”
ResultSelf-citationHypovitaminosis D and “small burden” uterine fibroids
Ciavattini, A., Carpini, G. D., Serri, M., Vignini, A., Sabbatinelli, J., Tozzi, A., Aggiusti, A., & Clemente, N. (2016) · Medicine · doi:10.1097/md.0000000000005698 · Cited by 80
Cogram, P., Hynes, A., Dunlevy, L. P. E., Greene, N. D. E., & Copp, A. J. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddh003 · Cited by 79 · cited 1×
“Indeed, both myo-Ins and D-chiro-Ins can prevent NTDs in the curly tail model, with the involvement of specific isoforms of protein kinase C [87,88].”
BackgroundInositol for the prevention of neural tube defects: a pilot randomised controlled trial
Greene, N. D. E., Leung, K., Gay, V., Burren, K. A., Mills, K. A., Chitty, L. S., & Copp, A. J. (2016) · British Journal Of Nutrition · doi:10.1017/s0007114515005322 · Cited by 79
Self-citationMetformin in Pregnancy: Mechanisms and Clinical Applications
Hyer, S., Balani, J., & Shehata, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071954 · Cited by 78
Hod, M., Star, S., Passonneau, J. V., Unterman, T. G., & Freinkel, N. (1986) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(86)90731-x · Cited by 77 · cited 1×
“Diabetic tissues are prone to be inositol-deficient and show high glucose concentration [97] and inositol depletion, as well as NTDs, are also found in rodent embryos exposed to hyperglycemia or induced diabetes [98,99].”
BackgroundSelf-citationModulation of gonadotrophin induced steroidogenic enzymes in granulosa cells by d-chiroinositol
Sacchi, S., Marinaro, F., Tondelli, D., Lui, J., Xella, S., Marsella, T., Tagliasacchi, D., Argento, C., Tirelli, A., Giulini, S., et al. (2016) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-016-0189-2 · Cited by 77 · cited 4×
“Accordingly, a decrease in ovarian aromatase expression was recorded, providing the first evidence of a specific downregulation of aromatase mediated by D-chiro-Ins in an in vivo system and supporting the observations on cultured human granulosa cells from Sacchi [31].”
BackgroundResultInfluential(2019) · PubMed · doi:10.26355/eurrev_201906_18223 · Cited by 75
Self-citationThe use of D-chiro-Inositol in clinical practice.
Gambioli, R., Forte, G., Aragona, C., Bevilacqua, A., Bizzarri, M., & Unfer, V. (2021) · PubMed · doi:10.26355/eurrev_202101_24412 · Cited by 75 · cited 3×
“The discovery that D-chiro-Ins modulates the expression of the aromatase enzyme, influencing steroidogenesis and consequently the androgen/estrogen balance [31], led to the consideration that D-chiro-Ins supplementation may be a valid approach for male and female clinical conditions that would benefit from androgen in…”
BackgroundSelf-citationCockroft, D. L. (1988) · Teratology · doi:10.1002/tera.1420380312 · Cited by 73 · cited 1×
“A direct requirement for inositol in neural tube closure was shown in rodents, in which inositol deficiency in whole embryo culture resulted in cranial NTDs [77,78].”
BackgroundIjuin, T., & Takenawa, T. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.335539 · Cited by 73 · cited 1×
“Intracellularly, myo-Ins promotes GLUT4 translocation to the plasma membrane to enhance glucose uptake, inhibits adenylate cyclase and reduces free fatty acid release from adipose tissue [15,16].”
BackgroundMetformin therapy and diabetes in pregnancy
Simmons, D., Walters, B. N. J., Rowan, J. A., & McIntyre, H. D. (2004) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2004.tb06024.x · Cited by 73
Larner, J., Price, J. D., Heimark, D. B., Smith, L., Rule, G. S., Piccariello, T., Fonteles, M. C., Pontes, C., Vale, D., & Huang, L. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030071j · Cited by 71 · cited 1×
“Larner and colleagues were the first to propose inositols as chemical insulin mediators [22,24,25].”
BackgroundBegum, M. R., Khanam, N. N., Quadir, E., Ferdous, J., Begum, M. S., Khan, F., & Begum, A. (2009) · Journal of Obstetrics and Gynaecology Research · doi:10.1111/j.1447-0756.2008.00876.x · Cited by 70
Sussman, I., & Matschinsky, F. M. (1988) · Diabetes · doi:10.2337/diab.37.7.974 · Cited by 69 · cited 1×
“Diabetic tissues are prone to be inositol-deficient and show high glucose concentration [97] and inositol depletion, as well as NTDs, are also found in rodent embryos exposed to hyperglycemia or induced diabetes [98,99].”
BackgroundInositol and human reproduction. From cellular metabolism to clinical use
Milewska, E. M., Czyzyk, A., Meczekalski, B., & Genazzani, A. D. (2016) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1188282 · Cited by 69 · cited 1×
“Based on this role, myoIns modulates the FSH-mediated anti-Mullerian hormone (AMH) production, playing a pivotal role in determining oocyte maturation and transport in the oviduct as well as ensuring the good quality of embryos [29].”
BackgroundCogram, P., Tesh, S. A., Tesh, J. M., Wade, A., Allan, G., Greene, N. D. E., & Copp, A. J. (2002) · Human Reproduction · doi:10.1093/humrep/17.9.2451 · Cited by 68 · cited 1×
“Indeed, both myo-Ins and D-chiro-Ins can prevent NTDs in the curly tail model, with the involvement of specific isoforms of protein kinase C [87,88].”
BackgroundYeung, C., Anapolski, M., Setiawan, I. B., Lang, F. J. W., & Cooper, T. G. (2004) · Journal of Andrology · doi:10.1002/j.1939-4640.2004.tb02781.x · Cited by 67
Monastra, G., Unfer, V., Harrath, A. H., & Bizzarri, M. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1247797 · Cited by 67
Self-citationManagement of Adverse Effects of Mood Stabilizers
Murru, A., Popović, D., Pacchiarotti, I., Hidalgo, D., Caballero, J. L., & Vieta, E. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0603-z · Cited by 64
Cockroft, D. L., Brook, F. A., & Copp, A. J. (1992) · Teratology · doi:10.1002/tera.1420450216 · Cited by 64 · cited 1×
“A direct requirement for inositol in neural tube closure was shown in rodents, in which inositol deficiency in whole embryo culture resulted in cranial NTDs [77,78].”
BackgroundSelf-citationInositol and folate resistant neural tube defects
Cavalli, P., & Copp, A. J. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.2.e5 · Cited by 64 · cited 1×
“Owing to the prevention of NTDs in the FA-resistant curly tail mouse model, 12 women with a history of FA-resistant NTDs, were counselled to take supplemental myo-Ins as a possible means to prevent NTD recurrence in a subsequent pregnancy [107,108].”
BackgroundSelf-citationFacchinetti, F., Appetecchia, M., Aragona, C., Bevilacqua, A., Bezerra Espinola, M. S., Bizzarri, M., D’Anna, R., Dewailly, D., Diamanti-Kandarakis, E., Hernández Marín, I., et al. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1737675 · Cited by 63 · cited 1×
“Several scientific studies have documented myo-Ins supplementation as a safe and efficient approach in treating PCOS symptoms, improving hormonal profile, hyperandrogenism, menstrual cycle, oocyte quality and psychological disturbances [54,195].”
BackgroundSelf-citationMinozzi, M., Nordio, M., & Pajalich, R. (2013) · PubMed · Cited by 62
Self-citationZheng, X., Lin, D., Zhang, Y., Lin, Y., Song, J., Li, S., & Sun, Y. (2017) · Medicine · doi:10.1097/md.0000000000008842 · Cited by 62 · cited 1×
“Similarly, another systematic review confirmed the efficacy of myo-Ins supplementation in improving clinical pregnancy rate and reducing the units of rFSH in infertile non-PCOS patients undergoing ovulation induction for ICSI or IVF and embryo transfer [138].”
Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women
Montanino Oliva, M., Buonomo, G., Calcagno, M., & Unfer, V. (2018) · Journal of Ovarian Research · doi:10.1186/s13048-018-0411-2 · Cited by 62
Self-citationCellular consequences of inositol depletion
Deranieh, R. M., & Greenberg, M. L. (2009) · Biochemical Society Transactions · doi:10.1042/bst0371099 · Cited by 61 · cited 1×
“All of these medications share the “inositol-depletion hypothesis”, put forward to explain their therapeutic mechanism [187].”
BackgroundNordio, M., & Basciani, S. (2017) · International Journal of Endocrinology · doi:10.1155/2017/2549491 · Cited by 61 · cited 1×
“Moreover, myo-Ins in combination with Selenium, has been reported to be effective in restoring euthyroidism in patients with subclinical hypothyroidism or autoimmune thyroiditis [196].”
BackgroundSelf-citationEffects of inositol supplementation in a cohort of mothers at risk of producing an NTD pregnancy
Cavalli, P., Tonni, G., Grosso, E., & Poggiani, C. (2011) · Birth Defects Research Part A Clinical and Molecular Teratology · doi:10.1002/bdra.22853 · Cited by 60 · cited 1×
“Owing to the prevention of NTDs in the FA-resistant curly tail mouse model, 12 women with a history of FA-resistant NTDs, were counselled to take supplemental myo-Ins as a possible means to prevent NTD recurrence in a subsequent pregnancy [107,108].”
Self-citationUeber eine neue, aus dem Muskelfleische gewonnene Zuckerart
Scherer (1850) · Justus Liebig s Annalen der Chemie · doi:10.1002/jlac.18500730303 · Cited by 59
Mohammadi, F., Varanloo, N., Nasrabadi, M. H., Vatannejad, A., Amjadi, F., Masroor, M. J., Bajelan, L., Mehdizadeh, M., Aflatoonian, R., & Zandieh, Z. (2019) · Cell and Tissue Banking · doi:10.1007/s10561-018-9731-0 · Cited by 59 · cited 1×
“Lastly, it should be mentioned that myo-Ins is also able to protect the sperm of infertile men undergoing assisted reproductive technology (ART) from alterations occurring during the cryopreservation procedure [124,125].”
BackgroundMyo-Inositol as a Key Supporter of Fertility and Physiological Gestation
Gambioli, R., Forte, G., Buzzaccarini, G., Unfer, V., & Laganà, A. S. (2021) · Pharmaceuticals · doi:10.3390/ph14060504 · Cited by 59
Self-citationMaternal Dietary Glycemic Intake and the Risk of Neural Tube Defects
Yazdy, M. M., Liu, S., Mitchell, A. A., & Werler, M. M. (2010) · American Journal of Epidemiology · doi:10.1093/aje/kwp395 · Cited by 58
Vitale, S. G., Corrado, F., Caruso, S., Benedetto, A. D., Giunta, L., Cianci, A., & D’Anna, R. (2020) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2020.1852191 · Cited by 57
Self-citationBattista, M.-C., Hivert, M.-F., Duval, K., & Baillargeon, J.-P. (2011) · Experimental Diabetes Research · doi:10.1155/2011/596060 · Cited by 55 · cited 1×
“Furthermore, infants delivered by women with a GDM diagnosis show an increased risk of impaired glucose regulation in later life, further extending the intergenerational cycle of obesity and diabetes [58].”
BackgroundLeung, K., Mills, K. A., Burren, K. A., Copp, A. J., & Greene, N. D. E. (2011) · Journal of Chromatography B · doi:10.1016/j.jchromb.2011.07.043 · Cited by 54 · cited 1×
“0 μM, which is significantly higher [185,186].”
Self-citationD’Anna, R., Corrado, F., Loddo, S., Gullo, G., Giunta, L., & Di Benedetto, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-88329-x · Cited by 54 · cited 1×
“Finally, interesting results were derived from the latest study by D’Anna and colleagues on GDM treatment [74].”
ResultSelf-citationEffect of Myoinositol and Antioxidants on Sperm Quality in Men with Metabolic Syndrome
Oliva, M. M., Minutolo, E., Lippa, A., Iaconianni, P., & Vaiarelli, A. (2016) · International Journal of Endocrinology · doi:10.1155/2016/1674950 · Cited by 53
Inositol activity in oligoasthenoteratospermia--an in vitro study.
Colone, M., Marelli, G., Unfer, V., Bozzuto, G., Molinari, A., & Stringaro, A. (2010) · PubMed · Cited by 52
Self-citationInsulin Mediators: Structure and Formation
Larner, J., Huang, L. C., Tang, G., Suzuki, S., Schwartz, C. F. W., Romero, G., Roulidis, Z., Zeller, K., Shen, T. Y., Oswald, A. S., et al. (1988) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1988.053.01.111 · Cited by 51 · cited 4×
“In spermatozoa, myo-Ins behaves as second messenger modulating the intracellular Ca2+ levels that regulate mitochondrial oxidative metabolism and ATP production [111].”
BackgroundInfluentialEspinola, M. S. B., Laganà, A. S., Bilotta, G., Gullo, G., Aragona, C., & Unfer, V. (2021) · American Journal of Case Reports · doi:10.12659/ajcr.932722 · Cited by 51
Self-citationAllan, S. J., Kavanagh, G. M., Herd, R. M., & Savin, J. A. (2004) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2004.05822.x · Cited by 50 · cited 1×
“Some studies reported a myo-Ins dose of 3–6 g/day could effectively promote recovery from the peripheral adverse effects without passing the blood brain barrier and hindering the beneficial central action of pharmacological treatments [197,198].”
BackgroundNESTLER, J. E., ROMERO, G., HUANG, L. C., ZHANG, C., & LARNER, J. (1991) · Endocrinology · doi:10.1210/endo-129-6-2951 · Cited by 50 · cited 1×
“Independently, Nestler and coworkers confirmed the insulin-mimetic action of a glycan containing D-chiro-Ins (called INS-2) on human ovarian thecal cells [27,28].”
BackgroundSelf-citationAltered Ovarian Inositol Ratios May Account for Pathological Steroidogenesis in PCOS
Unfer, V., Dinicola, S., Laganà, A. S., & Bizzarri, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197157 · Cited by 50 · cited 1×
“In this regard, higher myo-Ins/D-chiro-Ins ratios should increase aromatase activity in granulosa, fostering estrogen biosynthesis, while lower myo-Ins/D-chiro-Ins ratios promote androgen production in thecal cells [131].”
BackgroundSelf-citationInositols Depletion and Resistance: Principal Mechanisms and Therapeutic Strategies
Lepore, E., Lauretta, R., Bianchini, M., Mormando, M., Lorenzo, C. D., & Unfer, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136796 · Cited by 50
Self-citationEmekçi Özay, Ö., Özay, A. C., Çağlıyan, E., Okyay, R. E., & Gülekli, B. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1296127 · Cited by 49
Inositol Treatment for PCOS Should Be Science-Based and Not Arbitrary
Roseff, S., & Montenegro, M. (2020) · International Journal of Endocrinology · doi:10.1155/2020/6461254 · Cited by 49 · cited 1×
“Although other ratios were analyzed, these combinations were without a scientific rationale [51]; conversely the 40:1 ratio that may appear arbitrary, actually is similar to the plasma ratio reported in healthy women [51–54], thus supporting its supplementation to restore the physiological concentrations of myo-Ins an…”
ResultSelf-citationKrstevska, S. S., Bogoev, M. K., Bogoeva, K., Zisovska, E., Samardziski, I., Nakova, V. V., Livrinova, V., Todorovska, I., Sima, A., & Blazevska-Siljanoska, V. (2018) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2018.200 · Cited by 49
Chiu, T. T. Y., & Tam, P. (1992) · Journal of Assisted Reproduction and Genetics · doi:10.1007/bf01204248 · Cited by 48 · cited 1×
“In 1992 Chiu and colleagues first demonstrated the beneficial role for myo-Ins in IVF treatment [132].”
BackgroundSelf-citationFallahi, P., Ferrari, S. M., Ruffilli, I., Ragusa, F., Biricotti, M., Materazzi, G., Miccoli, P., & Antonelli, A. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1227782 · Cited by 48
Fan, C., Liang, W., Wei, M., Gou, X., Han, S., & Bai, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00354 · Cited by 48 · cited 1×
“Moreover, D-chiro-Ins increases mRNA and protein expression of IRS2, PI3K and AKT, upregulating the level of the P-AKT protein, and downregulating the level of the GSK3β protein [19] (Figure 2); all of which are key players in insulin and other hormone signal transduction.”
BackgroundGulino, F. A., Leonardi, E., Marilli, I., Musmeci, G., Vitale, S. G., Leanza, V., & Palumbo, M. A. (2016) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1080680 · Cited by 47
Alpha-lactalbumin Effect on Myo-inositol Intestinal Absorption: In vivo and In vitro
Monastra, G., Sambuy, Y., Ferruzza, S., Ferrari, D., & Ranaldi, G. (2018) · Current Drug Delivery · doi:10.2174/1567201815666180509102641 · Cited by 47 · cited 1×
“on 18 healthy volunteers [180] provided evidence that the combination of myo-Ins plus α-LA guarantees a greater bioavailability of myo-Ins, compared to when myo-Ins is administered alone.”
BackgroundSelf-citationcDNA cloning and gene expression analysis of human myo-inositol 1-phosphate synthase
Guan, G., Dai, P., & Shechter, I. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/s0003-9861(03)00388-6 · Cited by 46
Grainyhead genes and mammalian neural tube closure
Gustavsson, P., Copp, A. J., & Greene, N. D. E. (2008) · Birth Defects Research Part A: Clinical and Molecular Teratology · doi:10.1002/bdra.20494 · Cited by 44 · cited 1×
“Evidence for a potential protective effect of inositol for spinal NTDs comes from studies in the curly tail mouse strain, in which NTDs are not preventable by FA, modelling FA-resistant NTDs in humans [85].”
BackgroundSelf-citationRavanos, K., Monastra, G., Pavlidou, T., Goudakou, M., & Prapas, N. (2017) · PubMed · doi:10.26355/eurrev_201712_13940 · Cited by 43 · cited 4×
“The correlation between the levels of myo-Ins and D-chiro-Ins in FF and the blastocyst quality only received a clearer elucidation with the study of Ravanos and coworkers [30].”
BackgroundMethodInfluentialSelf-citationMonastra, G., Vazquez-Levin, M. H., Espinola, M. S. B., Bilotta, G., Laganà, A. S., & Unfer, V. (2021) · Basic and Clinical Andrology · doi:10.1186/s12610-021-00131-x · Cited by 43 · cited 1×
“[141] showed that supplementation with 1 g/day D-chiro-Ins for 1 month to male volunteers with altered glycemia and/or hormonal status reduced serum estrone and estradiol levels (−85.”
BackgroundSelf-citationGoto, M. P., & Goldman, A. S. (1994) · Current Opinion in Pediatrics · doi:10.1097/00008480-199408000-00023 · Cited by 42 · cited 1×
“In addition to the direct requirement for myo-Ins in formation of the neural tube, suboptimal inositol status may also play a role in the known association of maternal diabetes and obesity with NTDs [91,92].”
BackgroundMetabolic Syndrome features and risk of neural tube defects
Ray, J. G., Thompson, M. D., Vermeulen, M. J., Meier, C., WYATT, P. R., Wong, P.-Y., Summers, A. M., Farrell, S. A., & Cole, D. E. C. (2007) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-7-21 · Cited by 41
Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use
Carlomagno, G., De Grazia, S., Unfer, V., & Manna, F. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.662953 · Cited by 41 · cited 2×
“Based on this evidence, myo-Ins was manufactured in the form of a soft gel capsule, resulting in improved gastrointestinal absorption that allows a reduction of the administered dose by one-third compared to the powdered form to achieve the same circulating inositol level, and at the same time overcoming the dose-depe…”
BackgroundSelf-citationTHE FREE MYO‐INOSITOL CONCENTRATION OF ADULT AND FETAL TISSUES OF SEVERAL SPECIES
Battaglia, F. C., Meschia, G., Blechner, J. N., & Barron, D. H. (1961) · Quarterly Journal of Experimental Physiology and Cognate Medical Sciences · doi:10.1113/expphysiol.1961.sp001532 · Cited by 41 · cited 1×
“The high myo-Ins content in the developing central nervous system, skeletal, and cardiac muscle emphasizes the high embryonic demand for this nutrient [89].”
BackgroundArtini, P. G., Casarosa, E., Carletti, E., Monteleone, P. A. A., Noia, A. D., & Berardino, O. M. D. (2016) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1254179 · Cited by 39
Facchinetti, F., Cavalli, P., Copp, A. J., D’Anna, R., Kandaraki, E., Greene, N. D. E., Unfer, V., & for The Experts Group on Inositol in Basic and Clinical Research (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1828344 · Cited by 39
Self-citationWang, X., Ai, T., Meng, X. L., Zhou, J., & Mao, X. Y. (2014) · Journal of Dairy Science · doi:10.3168/jds.2013-7461 · Cited by 38 · cited 1×
“Recently, researchers proposed the concomitant administration of myo-Ins and the milk protein α-LA, already known for its properties as a nutrient as well as for enhancing the absorption of metal ions and vitamins [178,179].”
BackgroundHammoud, A., Carrell, D. T., Meikle, A. W., Xin, Y., Hunt, S. C., Adams, T. D., & Gibson, M. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.10.037 · Cited by 38 · cited 1×
“The reasons for this co-occurrence of obesity with hyperestrogenemia in men are not well defined but may include polymorphism in the aromatase gene CYP19A [151].”
Background(2019) · PubMed · doi:10.26355/eurrev_201903_17278 · Cited by 38
Self-citationHod, M., Star, S., Passonneau, J. V., Tg, U., & Freinkel, N. (1990) · PubMed · Cited by 38
Medical therapy for fibroids: An overview
Talaulikar, V. S. (2017) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2017.09.007 · Cited by 37
Garzon, S., Laganà, A. S., & Monastra, G. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1651839 · Cited by 37 · cited 1×
“observed that D-chiro-Ins, sorbitol and maltodextrin, when provided together with myo-Ins, significantly decreased its absorption and plasma concentration, compared to when myo-Ins was supplemented alone [7].”
BackgroundSelf-citationMohammadi, S., Eini, F., Bazarganipour, F., Taghavi, S. A., & Azizi, M. (2021) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-021-00741-0 · Cited by 37
Saquinavir Soft-Gel Capsule: An Updated Review of its Use in the Management of HIV Infection
Figgitt, D. P., & Plosker, G. L. (2000) · Drugs · doi:10.2165/00003495-200060020-00016 · Cited by 36
Mendoza, N., Diaz-Ropero, M. P., Aragon, M., Maldonado, V., Llaneza, P., Lorente, J., Mendoza-Tesarik, R., Maldonado-Lobon, J., Olivares, M., & Fonolla, J. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2019.1576620 · Cited by 36 · cited 1×
“On the other hand, one study [55] considers the amount of DCI in the 40:1 ratio very low and proposes combining the two inositols using D-chiro-Ins at high doses.”
BackgroundD'Souza, S. W., Copp, A. J., Greene, N. D. E., & Glazier, J. D. (2020) · Advances in Nutrition · doi:10.1093/advances/nmaa100 · Cited by 35 · cited 1×
“This suggests that active, carrier-mediated transport mechanisms for inositol are established early in pregnancy and/or there is substantial placental/fetal production of inositol [84].”
BackgroundSelf-citationClinical Use of Aromatase Inhibitors in Adult Males
Tan, R., Guay, A. T., & Hellstrom, W. J. G. (2014) · Sexual Medicine Reviews · doi:10.1002/smrj.23 · Cited by 33
Palmieri, M., Papale, P., Ragione, A. D., Quaranta, G., Russo, G., & Russo, S. (2016) · International Journal of Endocrinology · doi:10.1155/2016/2839041 · Cited by 33
Bevilacqua, A., Dragotto, J., Lucarelli, M., Emidio, G. D., Monastra, G., & Tatone, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115691 · Cited by 32 · cited 1×
“Accordingly, Bevilacqua and coworkers hypothesized that, like the aromatase inhibitor Letrozole, high doses of D-chiro-Ins administered to normal female mice would generate an androgenic PCOS-like model or other ovarian lesions [56].”
BackgroundSelf-citationRubino, P., Palini, S., Chigioni, S., Carlomagno, G., Quagliariello, A., Stefani, S. D., Baglioni, A., & Bulletti, C. (2015) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-014-0401-2 · Cited by 31
Joint position statement on universal screening for GDM in Europe by FIGO, EBCOG and EAPM
Hod, M., Pretty, M., & Mahmood, T. (2018) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2018.05.037 · Cited by 31 · cited 1×
“Therefore, the screening for GDM should be universal [59] and ideally conducted between 24–28 weeks of gestation.”
BackgroundSelf-citationMurthy, P. P. N. (2006) · Springer eBooks · doi:10.1007/0-387-27600-9_1 · Cited by 30 · cited 1×
“hexahydroxycyclohexane allows the formation of nine different isomers: cis-, epi, allo-, myo-, neo-, scyllo-, L-chiro-, D-chiro- and muco- inositol (Figure 1) [4].”
BackgroundAromatase Expression in Uterine Leiomyomata Is Regulated Primarily by Proximal Promoters I.3/II
Imir, A. G., Lin, Z., Yin, P., Deb, S., Yılmaz, B., Çetin, M., Çetin, A., & Bulun, S. E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2482 · Cited by 30 · cited 1×
“In accordance, several groups reported that aromatase is significantly overexpressed in myoma cells compared with the adjacent normal myometrium [157,158], leading to a high level of in situ estrogens that may contribute to the growth advantage of myomas through an intracrine/autocrine mechanism [159].”
BackgroundcDNA sequence for rkST1, a novel member of the sodium ion-dependent glucose cotransporter family
Hitomi, K., & Tsukagoshi, N. (1994) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(94)90110-4 · Cited by 28
Does myo-inositol effect on PCOS follicles involve cytoskeleton regulation?
Bizzarri, M., Cucina, A., Dinicola, S., Harrath, A. H., Alwasel, S. H., Unfer, V., & Bevilacqua, A. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2016.03.014 · Cited by 25 · cited 1×
“Moreover, myo-Ins could modulate ovarian steroidogenesis by rearranging cytoskeletal proteins [130].”
BackgroundSelf-citationNew clinical targets of d -chiro-inositol: rationale and potential applications
Laganà, A. S., Garzon, S., & Unfer, V. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1785429 · Cited by 25 · cited 2×
“Finally, D-chiro-Ins supplementation may be successfully used to decrease estrogen production and induce ovulation in anovulatory women [140].”
BackgroundSelf-citationMonastra, G., Vučenik, I., Harrath, A. H., Alwasel, S. H., Kamenov, Z. A., Laganà, A. S., Monti, N., Fedeli, V., & Bizzarri, M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.660381 · Cited by 25
Self-citationSpina bifida and genetic factors related to myo-inositol, glucose, and zinc
Groenen, P. M. W., Klootwijk, R., Schijvenaars, M. M. V. A. P., Straatman, H., Mariman, E. C. M., Franke, B., & Steegers‐Theunissen, R. P. M. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.03.007 · Cited by 24 · cited 1×
“However, a case-control trial study did not confirm this correlation [82].”
Analysis of inositol by high-performance liquid chromatography
Wang, W., Safar, J., & Zopf, D. (1990) · Analytical Biochemistry · doi:10.1016/0003-2697(90)90632-j · Cited by 24 · cited 1×
“Only many years later, Maquenne established the inositol cyclohexanol structure, purifying it from leaves [2], while a century later the elegant work of Posternak described the configuration of the main inositol isomer in eukaryotic tissues: myo-inositol (myo-Ins) [3].”
BackgroundAcute liver failure requiring transplantation caused by ulipristal acetate
Meunier, L., Meszaros, M., Pageaux, G., Delay, J.-M., Herrero, A., Pinzani, V., & Hillaire‐Buys, D. (2020) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2020.02.008 · Cited by 22
Miriello, D., Galanti, F., Cignini, P., Antonaci, D., Schiavi, M. C., & Rago, R. (2021) · PubMed · doi:10.26355/eurrev_202104_25537 · Cited by 22
Soft gel capsules improve melatonin’s bioavailability in humans
Proietti, S., Carlomagno, G., Dinicola, S., & Bizzarri, M. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.943183 · Cited by 21
Self-citationD-Chiro-Inositol Improves Sperm Mitochondrial Membrane Potential: In Vitro Evidence
Condorelli, R. A., Barbagallo, F., Calogero, A. E., Cannarella, R., Crafa, A., & Vignera, S. L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051373 · Cited by 21 · cited 2×
“Moreover, an excessively high MMP value might worsen sperm motility and quality, leading to an increased production of reactive oxygen species (ROS) [115].”
BackgroundSorbitol, Myo-Inositol and Sodium-Potassium ATPase in Diabetic Peripheral Nerve
Greene, D. A. (1986) · Drugs · doi:10.2165/00003495-198600322-00004 · Cited by 20 · cited 1×
“Diabetic tissues are prone to be inositol-deficient and show high glucose concentration [97] and inositol depletion, as well as NTDs, are also found in rodent embryos exposed to hyperglycemia or induced diabetes [98,99].”
BackgroundVartanyan, E. V., Ашотовна, Ц. К., Devyatova, E. A., Mikhaylyukova, A. S., Levin, V. A., Petukhova, N., Markin, A. V., & Steptsova, E. M. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1399699 · Cited by 20 · cited 1×
“Further demonstrations of myo-Ins efficacy came from two other studies: the first is an IVF clinical trial on 133 PCOS women [135], in which the authors reported that supplementation with 1 g myo-Ins and 400 μg folic acid significantly augmented the number of mature oocytes compared to the control group, treated with…”
ResultAsimakopoulos, G., Pergialiotis, V., Anastasiou, E., Antsaklis, P. G., Theodora, M., Vogiatzi, E., Kallergi, A., Sindos, M., Loutradis, D., & Daskalakis, G. J. (2020) · Trials · doi:10.1186/s13063-020-04561-2 · Cited by 19
Inositol treatment for psychological symptoms in Polycystic Ovary Syndrome women.
Cantelmi, T., Lambiase, E. A., Unfer, V., Gambioli, R., & Unfer, V. (2021) · PubMed · doi:10.26355/eurrev_202103_25278 · Cited by 18 · cited 1×
“Several scientific studies have documented myo-Ins supplementation as a safe and efficient approach in treating PCOS symptoms, improving hormonal profile, hyperandrogenism, menstrual cycle, oocyte quality and psychological disturbances [54,195].”
BackgroundSelf-citationSantoro, M., Aquila, S., & Russo, G. (2020) · Systems Biology in Reproductive Medicine · doi:10.1080/19396368.2020.1826067 · Cited by 17
Inositol Supplementation in the Prevention of Gestational Diabetes Mellitus
Tahir, F., & Majid, Z. (2019) · Cureus · doi:10.7759/cureus.5671 · Cited by 16 · cited 1×
“Two recent reviews summarized these trials, concluding that myo-Ins, rather than D-chiro-Ins or their combination, can lower GDM rates, improve gestational glycemia and lipid and insulin resistance parameters as well as reducing the need for insulin therapy should GDM develop later [69,70].”
BackgroundMyoinositol Improves Embryo Development in PCOS Patients Undergoing ICSI
Wdowiak, A. (2016) · International Journal of Endocrinology · doi:10.1155/2016/6273298 · Cited by 16 · cited 1×
“In a retrospective study Wdowiak demonstrated myo-Ins effectiveness on PCOS women undergoing intracytoplasmic sperm injection (ICSI), concluding that 2 g myo-Ins plus 200 μg folic acid twice a day increased embryo development dynamics and accelerated blastocyst stage reaching time [134].”
BackgroundSelf-citationMyo-inositol impact on sperm motility in vagina and evaluation of its effects on foetal development.
Oliva, M. M., Buonomo, G., Carra, M. C., Lippa, A., & Lisi, F. (2020) · PubMed · doi:10.26355/eurrev_202003_20540 · Cited by 15
Metformin in Pregnancy: Mechanisms and Clinical ApplicationsPreprint
Hyer, S. L., Balani, J., & Shehata, H. A. (2018) · Preprints.org · doi:10.20944/preprints201806.0091.v1 · Cited by 15
Nordio, M., Kumanov, P., Chiefari, A., & Puliani, G. (2021) · Basic and Clinical Andrology · doi:10.1186/s12610-021-00146-4 · Cited by 14
Self-citationPolycystic ovary syndrome in patients on antiepileptic drugs
Satishchandra, P., Viswanathan, L., Bhimani, B. C., Reddy, J. Y. C., Murthy, B. S. R., Subbakrishna, D. K., & Sinha, S. (2016) · Annals of Indian Academy of Neurology · doi:10.4103/0972-2327.179973 · Cited by 14
Tinelli, A., Gustapane, S., D’Oria, O., Licchelli, M., & Panese, G. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13692 · Cited by 14
Enhancement of D-chiro-inositol transport across intestinal cells by alpha-Lactalbumin peptides.
Ranaldi, G., Ferruzza, S., Natella, F., Unfer, V., Sambuy, Y., & Monastra, G. (2020) · PubMed · doi:10.26355/eurrev_202010_23234 · Cited by 11 · cited 1×
“The same effect, due to α-LA, was found also with D-chiro-Ins [183].”
BackgroundSelf-citationAdministration of inositol to a patient with bipolar disorder and psoriasis: a case report
Kontoangelos, K. A., Vaidakis, N., Zervas, I. M., Thomadaki, O. O., Christaki, S., Stavrianeas, N. G., & Papadimitriou, G. N. (2010) · Cases Journal · doi:10.1186/1757-1626-3-69 · Cited by 9 · cited 1×
“Some studies reported a myo-Ins dose of 3–6 g/day could effectively promote recovery from the peripheral adverse effects without passing the blood brain barrier and hindering the beneficial central action of pharmacological treatments [197,198].”
BackgroundDuality in the mechanism of action of insulin.
Larner, J., Romero, G. G., Kennington, A. S., Lilley, K., Kilgour, E., Zhang, C., Heimark, D. B., Gamez, G., Houston, D., & Huang, L. C. (1990) · PubMed · Cited by 9
Thalamati, S. (2019) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20190498 · Cited by 9
Sukegawa, G., & Tsuji, Y. (2020) · PubMed · doi:10.14989/actauroljap_66_11_407 · Cited by 5 · cited 1×
“In addition, another concern derives from the fact that exogenous testosterone can suppress the hypothalamic-pituitary-gonadal axis through negative feedback, and TRT may lead to secondary spermatogenic failure and subsequent infertility [144].”
Background
Research works printed but not linked: 2
- Maquenne, 1887, Préparation, proprietés et constitution se l’inosite, CR Hebd. Séance Acad. Sci. Paris, 104, 225
- 2021, D-Chiro-Inositol, vitamin D and epigallocatechin gallate avoid surgery in women with uterine fibroids: 2 case reports, Eur. Med. J., 9, 95
Cited by
Zhao, H., Zhang, J., Cheng, X., Nie, X., & He, B. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-022-01091-0 · Cited by 408
“proportion of DCI improves the health of organs and tissues, while long-term high-dose DCI monotherapy in women with PCOS has a negative impact [184].”
BackgroundArmanini, D., Boscaro, M., Bordin, L., & Sabbadin, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084110 · Cited by 324
“On the contrary, the supplementation of DCI alone may worsen the insulin-mediated androgen synthesis and fertility in PCOS women [53].”
BackgroundResultGreff, D., Juhász, A. E., Váncsa, S., Váradi, A., Sipos, Z., Szinte, J., Park, S., Hegyi, P., Nyirády, P., Ács, N., et al. (2023) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-023-01055-z · Cited by 143
“During the secondary signaling mechanisms, inositol triphosphate (IP3) will also be released, which can be converted to free myoinositol by inositol-monophosphatase [6].”
BackgroundInfluentialFitz, V., Graca, S., Mahalingaiah, S., Liu, J., Lai, L., Butt, A., Armour, M., Rao, V., Naidoo, D., Maunder, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad762 · Cited by 70
“Mechanistically, MI promotes translocation of the glucose transporter type 4 to the plasma membrane for glucose uptake (7) and also reduces release of free fatty acids from adipose tissue (8).”
BackgroundEffect of gestational diabetes mellitus on lipid profile: A systematic review and meta-analysis
Rahnemaei, F. A., Pakzad, R., Amirian, A., Pakzad, I., & Abdi, F. (2021) · Open Medicine · doi:10.1515/med-2021-0408 · Cited by 83
“They are effective alternatives to classical insulin sensitizers and are useful in the prevention and treatment of metabolic and reproductive disorders such as polycystic ovary syndrome and GDM [2,3].”
Background
Metadata
- Authors
- Dinicola, S., Unfer, V., Facchinetti, F., Soulage, C. O., Greene, N. D., Bizzarri, M., Laganà, A. S., Chan, S.-Y., Bevilacqua, A., Pkhaladze, L., Benvenga, S., Stringaro, A., Barbaro, D., Appetecchia, M., Aragona, C., Bezerra Espinola, M. S., Cantelmi, T., Cavalli, P., Chiu, T. T., Copp, A. J., D’Anna, R., Dewailly, D., Di Lorenzo, C., Diamanti-Kandarakis, E., Hernández Marín, I., Hod, M., Kamenov, Z., Kandaraki, E., Monastra, G., Montanino Oliva, M., Nestler, J. E., Nordio, M., Ozay, A. C., Papalou, O., Porcaro, G., Prapas, N., Roseff, S., Vazquez-Levin, M., Vucenik, I., & Wdowiak, A.
- Affiliations
- Systems Biology Group Lab, 00161 Rome, Italy
- University of Modena and Reggio Emilia (IT)
- Lyon 1 Université (FR)
- University College London (GB)
- Sapienza University of Rome (IT)
- University of Insubria (IT)
- National University of Singapore (SG)
- Zhordania and Khomasuridze Institute of Reproductology, Tbilisi 0112, Georgia
- University of Messina (IT)
- Istituto Superiore di Sanità (IT)
- Ospedale di Livorno (IT)
- Instituto Nazionale Tumori Regina Elena (IT)
- Institute for Interpersonal Cognitive Therapy, 00100 Rome, Italy
- IRCCS Humanitas Research Hospital (IT)
- IVF Centre, Hong Kong 999077, China
- Université de Lille (FR)
- Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome Polo Pontino, 04100 Latina, Italy
- Department of Endocrinology and Diabetes, HYGEIA Hospital, Marousi, 15123 Athens, Greece
- Human Reproduction Department, Hospital Juárez de México, Universidad Nacional Autónoma de México (UNAM), Mexico City 07760, Mexico
- Tel Aviv University (IL)
- Medical University of Sofia (BG)
- Hygeia Hospital (GR)
- Department of Obstetrics and Gynecology, Santo Spirito Hospital, 00193 Rome, Italy
- Virginia Commonwealth University (US)
- A.S.L. RMF, 00053 Civitavecchia, Italy
- Department of Obstetrics and Gynecology, Near East University Hospital, Nicosia 99138, Cyprus
- Azienda Unità Sanitaria Locale Umbria n. 2 (IT)
- Iakentro (GR)
- Reproductive Endocrinology and Infertility, South Florida Institute for Reproductive Medicine (IVFMD), Boca Raton, FL 33458, USA
- Instituto de Biología y Medicina Experimental (IBYME, CONICET-FIBYME), Consejo Nacional de Investigaciones Científicas y Técnicas de Argentina (CONICET), Buenos Aires 2490, Argentina
- Department of Medical & Research Technology and Pathology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA
- Medical University of Lublin (PL)
- Corresponding author
- Facchinetti, Fabio
- ORCID
- Dinicola, Simona
- Unfer, Vittorio
- Facchinetti, Fabio
- Soulage, Christophe O.
- Greene, Nicholas D.
- Bizzarri, Mariano
- Laganà, Antonio Simone
- Chan, Shiao-Yng
- Bevilacqua, Arturo
- Pkhaladze, Lali
- Benvenga, Salvatore
- Stringaro, Annarita
- Barbaro, Daniele
- Appetecchia, Marialuisa
- Cavalli, Pietro
- Copp, Andrew J.
- D’Anna, Rosario
- Dewailly, Didier
- Di Lorenzo, Cherubino
- Diamanti-Kandarakis, Evanthia
- Kamenov, Zdravko
- Kandaraki, Eleni
- Monastra, Giovanni
- Nordio, Maurizio
- Ozay, Ali C.
- Papalou, Olga
- Roseff, Scott
- Wdowiak, Artur
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-09-30
- Volume
- 22
- Issue
- 19
- Pages
- 10575
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8508595
- OpenAlex
- W3203286644
- Cited by
- 154
- References
- 201
- Citations by year
- 2026: 24 · 2025: 30 · 2024: 29 · 2023: 43 · 2022: 27 · 2021: 1
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
- National University of Singapore (submittedVersion, cc-by)
- HAL (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- LillOA (Université de Lille (University Of Lille)) (submittedVersion)
- Funders
- Action Medical Research
- Sparks (17ICH03)
- Medical Research Council (MR/T003847/1)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- myo-inositol, D-chiro-inositol, steroidogenesis, aromatase, testosterone production, polycystic ovary syndrome, gestational diabetes mellitus, male fertility, sperm abnormalities, insulin sensitizers, inositol supplementation
- MeSH terms
- Female, Humans, Inositol, Polycystic Ovary Syndrome, Pregnancy, Testosterone, Theca Cells, Molecular Structure, Signal Transduction, Diabetes, Gestational
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.